This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...

This paper sheds light on some unexpected consequences of health insurance regulation that may pose a big challenge to insurers' risk management. Because mandated uniform contributions to health insurance trigger risk selection efforts risk adjustment (RA) schemes become necessary. A good deal...

Internationale Vergleiche von Krankenhausleistungen sind bislang selten. Die vorliegende Analyse untersucht die Effizienz der Krankenhäuser in Sachsen und der Schweiz mittels der Data Envelopment Analysis (DEA), einem Verfahren zur Ermittlung der effizienten Grenze. Dabei wird im Sinne eines...

Internationale Vergleiche von Krankenhausleistungen sind bislang selten. Die vorliegende Analyse untersucht die Effizienz der Krankenhäuser in Sachsen und der Schweiz mittels der Data Envelopment Analysis (DEA), einem Verfahren zur Ermittlung der effizienten Grenze. Dabei wird im Sinne eines...

This paper sheds light on some unexpected consequences of health insurance regulation that may pose a big challenge to insurers’ risk management. Because mandated uniform contributions to health insurance trigger risk selection efforts risk adjustment (RA) schemes become necessary. A good deal...

This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...

When premiums are community-rated, risk adjustment (RA) serves to mitigate competitive insurers’ incentive to select favorable risks. However, unless fully prospective, it also undermines their incentives for efficiency. By capping its volume, one may try to counteract this tendency, exposing...

This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...